A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
Jennifer J. Knox(National Cancer Center), Lesley Seymour(Queen's University), Nancy Wainman(Queen's University), Sharlene Gill(Deventer Ziekenhuis), C. Cripps(Canadian Partnership Against Cancer), Elizabeth A. Eisenhauer(Queen's University), Pierre Major(Juravinski Cancer Centre), Timothy W. Synold(St. Jude Children's Research Hospital), Ron Feld(University Health Network), James Biagi(Queen's University)
Cited by 67
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
|Journal of Clinical Oncology|2009|643